Wellington Shields Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Wellington Shields Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55M	Hold	45,773	–	–	0.2%	91
2026 Q1	$1.38M	Hold	45,773	–	–	0.21%	88
2025 Q4	$1.43M	Hold	45,773	–	–	0.21%	86
2025 Q3	$925K	Sell	45,773 -1,927	-4%	-$33.8K	0.14%	116
2025 Q2	$799K	Sell	47,700 -800	-2%	-$12.9K	0.14%	118
2025 Q1	$745K	Buy	+48,500	New	+$866K	0.14%	112
2013 Q4	–	Sell	-8,152	Closed	-$308K	–	336
2013 Q3	$308K	Sell	8,152 -704	-8%	-$27.5K	0.06%	235
2013 Q2	$347K	Buy	+8,856	New	+$345K	0.06%	237

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Wellington Shields Capital Management's TEVA Position: Q2 2026 in Review

Wellington Shields Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 45,773 shares worth $1.55M. The position accounts for 0.2% of the portfolio, ranked #91.

Wellington Shields Capital Management first reported a position in TEVA in Q2 2013 and has held it in 8 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Wellington Shields Capital Management held 45,773 shares of Teva Pharmaceuticals worth $1.55M as of Q2 2026.
Wellington Shields Capital Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up 0.2% of Wellington Shields Capital Management's portfolio in Q2 2026, its #91 holding.
Wellington Shields Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Wellington Shields Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.